HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The use of danazol in the management of chronic immune thrombocytopenic purpura.

Abstract
Danazol has recently been reported to be an effective mode of treatment for patients with refractory immune thrombocytopenic purpura. Following a 3 month trial of danazol, only one of 10 patients experienced a sustained increase in platelet counts and two other patients had a transient improvement. While the drug was well tolerated, it does not appear to be particularly helpful in the management of these patients.
AuthorsB A McVerry, M Auger, A J Bellingham
JournalBritish journal of haematology (Br J Haematol) Vol. 61 Issue 1 Pg. 145-8 (Sep 1985) ISSN: 0007-1048 [Print] England
PMID4052322 (Publication Type: Journal Article)
Chemical References
  • Pregnadienes
  • Danazol
Topics
  • Adult
  • Aged
  • Autoimmune Diseases (blood, drug therapy)
  • Chronic Disease
  • Danazol (therapeutic use)
  • Female
  • Humans
  • Male
  • Middle Aged
  • Platelet Count
  • Pregnadienes (therapeutic use)
  • Purpura, Thrombocytopenic (blood, drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: